Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.60 |
| ▸ | CCKBR | P32239 | 3/20 | 0.58 |
| ▸ | NPY1R | P25929 | 3/20 | 0.56 |
| ▸ | NPY2R | P49146 | 3/20 | 0.56 |
| ▸ | NPY4R | P50391 | 3/20 | 0.56 |
| ▸ | GHSR | Q92847 | 5/20 | 0.55 |
| ▸ | GRPR | P30550 | 1/20 | 0.55 |
| ▸ | CCKAR | P32238 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30366588 | 1.00 | KISS1R (0.60) | KISS1RCCKBRNPY1RNPY2RNPY4R | |
| SCHEMBL30494060 | 0.97 | KISS1R (0.60) | KISS1RCCKBRNPY1RNPY2RNPY4R | |
| SCHEMBL29849030 | 0.95 | NPY1R (0.57) | KISS1RCCKBRNPY1RNPY2RNPY4R | |
| SCHEMBL30618455 | 0.95 | NPY1R (0.57) | KISS1RCCKBRNPY1RNPY2RNPY4R | |
| SCHEMBL29519677 | 0.92 | KISS1R (0.57) | KISS1RCCKBRNPY1RNPY2RNPY4R | |
| SCHEMBL29399016 | 0.85 | GHSR (0.68) | KISS1RNPY1RNPY2RNPY4RGHSR | |
| SCHEMBL29402231 | 0.84 | GHSR (0.69) | KISS1RNPY1RNPY2RNPY4RGHSR | |
| SCHEMBL29357687 | 0.84 | KISS1R (0.62) | KISS1RMC4R | |
| SCHEMBL29559198 | 0.83 | NPY1R (0.65) | KISS1RCCKBRNPY1RNPY2RNPY4R | |
| SCHEMBL31332219 | 0.80 | CCKBR (0.55) | KISS1RCCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-113272330-B | Bispecific antibody | 南通壹宸生物医药科技有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-117979954-A | Corticotropin peptide compositions and methods of use | 辉凌有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240043473-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230263944-A1 | DUAL FUNCTION SURFACE FOR CELL CAPTURE AND SPREADING | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-08-24 | — | — | US | disclosed |
| CN-113226290-B | Hafnia alvei composition comprising mineral elements | 塔基迪有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-112980967-B | Method for colony breeding of easy-to-eat compound feed for micropterus salmoides | 中国水产科学研究院珠江水产研究所 | 2023-03-14 | — | — | CN | disclosed |
| CN-115066254-A | Human anti-inflammatory peptides for inhalation treatment of inflammatory lung diseases | 阿德维塔生命科学有限责任公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-109310736-B | Hafnia alvei-based pharmaceutical and food compositions for inducing satiety and prolonging satiety | 国立卫生研究所 | 2022-09-13 | — | — | CN | disclosed |
| CN-111019925-B | Method for screening protease variants and protease variants obtained | 上饶市康可得生物科技有限公司 | 2022-08-23 | — | — | CN | disclosed |
| WO-2022173827-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-112626227-B | SNPs sites related to appetite suppression of micropterus salmoides and application thereof | 中国水产科学研究院珠江水产研究所 | 2022-08-02 | — | — | CN | disclosed |
| CN-109824772-B | Gene recombination human corticotropin precursor for improving serum glucocorticoid level and preparation method thereof | 海南大学 | 2022-07-29 | — | — | CN | disclosed |
| EP-3973978-A1 | METHODS OF MODULATING CORTICOSTEROID RESPONSE | Mallinckrodt Ard IP Unlimited Company (IE) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | KISS1R 1232/4885CCKBR 257/4885NPY1R 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.